Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Psychological Distress and Type 2 Diabetes (COPEST)

17. Januar 2020 aktualisiert von: Azienda Ospedaliera Universitaria Integrata Verona

Glycaemic Control, Body Weight and Psychological Distress in Type 2 Diabetes: The Role of Self-Efficacy

Increasing evidence suggests that psychological disorders play an important role in the development and worsening of type 2 diabetes (T2D). Among the spectrum of psychological disorders, there is a wide literature about the association between depression and T2D and current data show an approximately two-fold prevalence of depression in adults affected by diabetes compared to un-affected subjects. Moreover, depression in diabetic patients is associated with higher blood glucose levels, poorer adherence to therapeutic regimens (whether pharmacological or therapeutic lifestyle changes), more medical complications, and higher hospitalization rates. Nevertheless, at the best of our knowledge, the mechanism underlying the association between depression and adverse diabetes-related outcomes is currently unresolved.

Aim of this project is to assess the efficacy of a psychological treatment for diabetic patients with suboptimal level of Hemoglobin A1c. This project is a RCT that seeks to address the question if type 2 diabetic patients with suboptimal glycaemic control would benefit from a specific psychological intervention, as specified below. A total of 80 diabetic patients will be recruited and randomly assigned to two treatment arms:

  1. Standard diabetes care
  2. 24 individual sessions of psychological intervention The expected main outcome is the improvement of glycaemic control under psychological intervention in 38 weeks of follow up.

Secondary outcomes: reduction of depression and anxiety, improvement in self-efficacy, perceived interference caused by diabetes, family support and eating problems.

Studienübersicht

Status

Suspendiert

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Several studies have reported higher level of psychological disorders in people with diabetes such as depression and anxiety. A recent meta-analysis suggests that the odds of depression in the diabetic patients is twice than in nondiabetic subjects and this difference persists even after adjustment for sex, type of diabetes or assessment method. Furthermore, depression is significantly associated with hyperglycemia. Several proposals exist to explain this association.

The aim of this project is to study the effect of a psychological intervention based on cognitive-behavioural strategies in patients with type II diabetes. The effect will be evaluate on both physiological and psychosocial parameters. The hypothesis is that a psychological intervention based on cognitive behavioural strategies increases patient's belief in his self-efficacy to succeed in diabetes care. The improvement in self-efficacy will therefore lead to improve the psychological status, i.e. depression.

Material and Methods: The investigators will perform a randomized controlled trial (RCT). A sample of 80 type 2 diabetic patients will be recruited at Endocrinology Unit of Verona Hospital during routine medical examination and then randomly assigned to intervention or control arm. In details, patients will be first recruited for participation in the study by their physician. Thereafter, patients will be approached by psychologist who will explain research and its goals. Control group will receive current standard of diabetes care. Intervention group will receive a weekly psychological intervention based on cognitive behavioural strategies. Each session will be based on self-monitoring, problem solving and goal setting. The first session will be held two weeks after the enrollment and the last one will take place at twenty-sixth week. Subjects will be given a food and physical activity diary as well as a pedometer. Study participants will weekly fill in the diary starting from 2nd session until the 19th session for a total of 18 weeks. Subjects will carry the pedometer for the same time window.

The psychological intervention comprises three phases:

PHASE 1 (1°-2° session):

  • Psychological testing
  • Therapeutic alliance formation
  • Goal definition

PHASE 2 (3°-19°)

  • Food and physical activity self-monitoring
  • Identifying unhealthy behaviours and helping subject to change them
  • Identifying negative beliefs and replace them with positive and healthy ones
  • Providing coping strategies to stress and emotions

PHASE 3 (20°-24°)

  • Reinforcing behaviour modification
  • Identifying possible barriers
  • Activation of personal and social resources

Outcome measures will be assessed at baseline (pre-treatment), after 26 weeks treatment (post-treatment) and at 38 weeks follow up (follow-up).

Studientyp

Interventionell

Einschreibung (Tatsächlich)

61

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Italien
      • Verona, Italien, 37126
        • Division of Endocrinology and Metabolic Diseases

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

25 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Type 2 diabetes diagnosed at least 1 year before enrollment
  • 25 ≤ BMI ≤ 40 Kg⋅m-2
  • 25 to 75 years
  • HbA1c > 7,0%

Exclusion Criteria:

  • Current schizophrenia/ psychotic disorders, bipolar disorders, addictive disorders, personality disorders
  • Current psychotherapy
  • Severe physical illness (i.e. cancer)
  • Pregnancy
  • Eligibility to bariatric surgery

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Psychological Intervention
Cognitive Behavioural Intervention
Verhalten: Cognitive-Behavioral Intervention

1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:

  • self-monitoring
  • problem solving
  • goal definition
  • cognitive restructuring
  • activation of personal and social resources
Kein Eingriff: Current standard of care

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline glycosylated haemoglobin (HbA1c) at 26th and 38th weeks [mmol/mol]
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)
Glycosylated haemoglobin (HbA1c) is a lab test that shows the average level of blood glucose over the previous 3 months. HbA1c is used in the present study as measure of the glycaemic control: it will be assessed at baseline (pre-treatment), after 26 weeks treatment (post-treatment) and at 38 weeks follow up (follow-up).
Baseline, 26 weeks (post-treatment)-38 weeks (FU)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline Body Mass Index (BMI)at 26th and 38th weeks [Kg/m2]
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
Body Mass Index is a measure of adiposity and is used here as anthropometric marker of life style change.
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
Change from baseline depressive symptoms at 26th and 38th weeks (BDI-II score)
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]

The Beck Depression Inventory II is a 21-item questionnaire developed to assess the intensity of depression as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV). The BDI-II items include (1) cognitive symptoms such as sadness and pessimism, (2) affective symptoms such as loss of pleasure and loss of interest, (3) somatic symptoms such as loss of energy, appetite changes and changes in sleep pattern.

The BDI-II is calculated by summing the ratings for the 21 items. The 4-point scale ranges from 0 to 3 for each item. The maximum total score is 63.

The measurement of outcome variables will be conducted 38 weeks after termination of the treatment (38 weeks follow up). The difference of the BDI-II scores among baseline (pretreatment), at the end of the 26 weeks treatment (post-treatment), and at 38 weeks follow up (follow-up) will be also calculated.
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
Change from baseline anxiety symptoms at 26th and 38th weeks(BAI score)
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]

The Beck Anxiety Inventory is a 21- item questionnaire developed to assess the severity of an anxiety in adult and adolescents. The items in the BAI describe the emotional, physiological and cognitive symptoms of anxiety.

The 4-point scale ranges from 0 to 3 for each item. The maximum total score is 63.

The decisive measurement of the outcome variables will be conducted 38 weeks after termination of the treatment (38 weeks follow up). The difference of the BDI-II scores among baseline (pretreatment), at the end of the 26 weeks treatment (post-treatment), and at 38 weeks follow up (follow-up) will be also calculated.
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
Change from baseline general perceptions of diabetes at 26th and 38th weeks (MDQ Section 1 score)
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]

The Multidimensional Diabetes Questionnaire (MDQ) was designed to provide a comprehensive assessment of diabetes-related cognitive and social factors. It includes 41 items subcategorized in three sections. The first section assesses the general perceptions of diabetes and related social support. It is comprised of three scales. These scales targets:

  1. perceived interference caused by diabetes to daily activities, work and social activities (9 items);
  2. perceived severity of diabetes ( 3 items);
  3. perceived diabetes-related social support from a significant other such as family, friends and health professionals (4 items).

Responses were rated on 7-point rating scales (from 0 to 6), with higher scores indicating higher levels of perceived interference, social support and severity.
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
Change from baseline family support at 26th and 38th weeks (MDQ section II score)
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
This section of the MDQ measures social incentives in relation to self-care activities. The scales included in this section were designed to measure the frequency of positive reinforcing behaviour (8 items) and the frequency of non supportive behaviours (4 items). Subjects recorded their responses on 7-point Likert scales (from 0 to 6) with higher scores indicating higher levels of positive and negative reinforcement behaviours.
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
Change from baseline Diabetes Self-Efficacy at 26th and 38th weeks (MDQ section III score)
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
This section of the MDQ is used to assess self-efficacy expectancies (7 items) and outcome expectancies (6 items). The self-efficacy scale measured patients' confidence in their ability to perform behaviours specific to the diabetes self-care activities. Responses were rated on a 0 to 100 rating scale. The outcome expectancies scale assessed patients' perceptions of the effect of diabetes self-care behaviours on metabolic control. Responses were rated on a 0 to 100 rating scale.
Baseline, 26 weeks (post-treatment)-38 weeks (FU)]
Change from baseline Binge-Eating Disorders at 26th and 38th weeks (BES score)
Zeitfenster: Baseline, 26 weeks (post-treatment)-38 weeks (FU)

The Binge-Eating Scale (BES) is a 16-item questionnaire developed to assess the presence of binge eating behaviour indicative of eating disorders. The BES includes questions on subjects' concerns about weight and food, inability to control urges to eat, feelings of guilt after eating and frequency of strict dieting.

Each question has 3-4 separate responses assigned a numerical value. The score ranges is from 0-46
Baseline, 26 weeks (post-treatment)-38 weeks (FU)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona

Ermittler

  • Hauptermittler: Enzo Bonora, MD, Universita di Verona

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Oktober 2012

Primärer Abschluss (Tatsächlich)

1. März 2015

Studienanmeldedaten

Zuerst eingereicht

19. April 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Juni 2013

Zuerst gepostet (Schätzen)

5. Juni 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. Januar 2020

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. Januar 2020

Zuletzt verifiziert

1. Januar 2020

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CE-2212 Ago, 29 2012

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Typ 2 Diabetes

Klinische Studien zur Cognitive-Behavioral Intervention

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Philippines

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren